Getting to Know Dr Doug Marks, Oncology Clinical Trialist
February 20th 2024Douglas K. Marks, MD, is a breast medical oncologist and director of the Clinical Trials Office, Perlmutter Cancer Center, NYU Langone Hospital—Long Island, as well as associate professor in the Department of Medicine at NYU Grossman Long Island School of Medicine. As a phase 1 clinical trialist, he sees both patients with breast cancer and those who are looking to receive innovative treatments for their early-stage disease.
Read More
Swedish Study Links False-Positive Mammograms to Elevated Breast Cancer Risk
February 16th 2024Swedish women with prior false-positive mammograms, particularly those aged 60 to 75 with prior biopsies and low density, show elevated breast cancer risk, necessitating closer monitoring and better screening.
Read More
Cultural Influences, Surgical Decision-Making Approaches for Non-Caucasian Women With Breast Cancer
February 14th 2024Non-Caucasian patients with breast cancer face common influences in surgical decision-making due to fear, misinformation, cultural factors, and power dynamics, highlighting the need for patient-centered surgical decision-making.
Read More
Neoadjuvant/Adjuvant Pembrolizumab Regimen Continues to Show EFS Benefit in High-Risk Early TNBC
December 27th 2023The 5-year event-free survival EFS) rate was 81.3% with neoadjuvant pembrolizumab/chemotherapy followed by adjuvant pembrolizumab compared with 72.3% in those who received placebo/chemotherapy plus placebo.
Read More
Top 5 Most-Read Breast Cancer Articles of 2023
December 24th 2023In breast cancer coverage this year, topline results from the phase 3 NATALEE trial made waves in March, with our other most-read content in the space covering an expanded indication for abemaciclib, revised screening recommendations, a new potential treatment to reduce radiation exposure, and the benefits of diet and exercise on patient outcomes.
Read More
Neoadjuvant KN026 Plus Docetaxel Demonstrate Early Activity in HER2+ Breast Cancer
December 22nd 2023A combination of KN026, a novel bispecific antibody, and docetaxel elicited responses with an acceptable toxicity profile when administered as neoadjuvant treatment in patients with HER2-positive (HER2+) early or locally advanced breast cancer.
Read More
Higher Survival Rates Found in Male Hispanic, API Patients With Early Breast Cancer
December 18th 2023These findings suggest that addressing socioeconomic disparities and inequities that impact access to health care and services may help improve survival outcomes across racial/ethnic groups of male patients with early breast cancer.
Read More
ICYMI: Highlights From the ACCC Fall National Oncology Conference
December 11th 2023This year’s top content from the fall meeting of the Association of Community Cancer Centers (ACCC) highlights both treatment gains made through innovative referral, screening, and assistance initiatives and the ongoing need to improve health equity and research inclusivity.
Read More
Trastuzumab Biosimilar Gets Go Ahead in EU for HER2+ Breast and Metastatic Gastric Cancers
December 5th 2023EG12014, a biosimilar of the anti-HER2 monoclonal antibody trastuzumab, has received a marketing authorization from the European Commission for use in the European Union (EU) for the treatment of patients with HER2-positive (HER2+) breast and metastatic gastric cancer; these are the same indications that trastuzumab holds in the European Union.
Read More
The FDA has approved capivasertib plus fulvestrant for the treatment of patients with HR-positive, HER2-negative, locally advanced or metastatic breast cancer harboring 1 or more PIK3CA, AKT1, or PTEN alteration, following progression on at least 1 endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.
Read More
Rhenium Obisbemeda for Breast Cancer, Leptomeningeal Metastases Receives ODD From FDA
November 6th 2023Rhenium (186Re) obisbemeda (Plus Therapeutics) shows potential to address the unmet need of new treatment options for patients with breast cancer and leptomeningeal metastases and will continue to be evaluated in the ReSPECT-LM program. The orphan drug designation (ODD) was granted on November 3.
Read More
Wide Variation Seen in County-Level Breast Cancer Mortality Linked to SDOH
November 4th 2023Data from 2176 US counties link obesity and higher breast cancer mortality, while also showing varying degrees of association between mortality and access to healthy lifestyle options per social determinants of health (SDOH).
Read More
Racial, Ethnic Disparities Seen in Breast Cancer Survival, Even Among Clinical Trial Participants
October 25th 2023It is critical to understand the role race and ethnicity play in survival for patients with early-stage breast cancer (eBC), as well as explore potential interventions to close these gaps.
Read More
Opt-In vs Opt-Out Patient Outreach Programs Yield Similar Mammography Completion Rates
October 21st 2023No differences in mammography completion were observed between an automated opt-out vs an opt-in patient outreach program for breast cancer screening, according to a randomized controlled trial. However, differences in administration burden between programs could lead clinics to prefer one over the other.
Read More
Contributor: Advancing Breast Cancer Treatment—The Role of Clinical Trials and the Path Ahead
October 11th 2023Clinical studies have transformed how breast cancer is prevented, identified, and treated. Successful clinical trials improve patient outcomes, so trial administrators must ensure participants receive appropriate support at trial enrollment.
Read More
FDA Grants Fast Track Designation to IDE161 for Select Pretreated BRCA1/2-Mutated HR+ Breast Cancer
October 6th 2023The FDA has granted fast track designation to IDE161 for use in adult patients with advanced or metastatic hormone receptor–positive, HER2-negative breast cancer harboring BRCA1/2 mutations who have progressed after at least 1 hormonal therapy, a CDK4/6 inhibitor, and a poly (ADP-ribose) polymerase inhibitor.
Read More
Dato-Dxd Shows Survival Improvements in HR+/HER2– Breast Cancer
September 29th 2023The dual primary end points of overall survival and progression-free survival were encouraging when patients with hormone receptor–positive (HR+), HER2-negative (HER2–) breast cancer were treated with datopotamab deruxtecan.
Read More
Breast Cancer Risk Linked to Air Pollution Exposure
September 22nd 2023Data from 6 states—California, Florida, Louisiana, New Jersey, North Carolina, and Pennsylvania—and 2 metropolitan areas—Atlanta, Georgia, and Detroit, Michigan—collected through the National Institutes of Health–AARP Diet and Health Study were used for the investigation.
Read More
Diet and Exercise Intervention Associated With Better pCR in TNBC or HR+, HER2– BC
September 16th 2023Despite seeming to elicit more pathological complete responses (pCRs) in patients with hormone receptor–positive (HR+), HER2-negative triple-negative breast cancer (BC) receiving neoadjuvant chemotherapy, diet and exercise did not affect relative dose intensity.
Read More
Regional Disparities Remain in Breast Reconstruction for Patients With Breast Cancer
September 15th 2023While regional variations were identified in rates of breast reconstruction, complications, and cost for patients with breast cancer, these differences did not seem to be associated with any implicit bias.
Read More